Sponsored Research and Clinical Trial Agreements - Summary of Aevitas expense related to its sponsored research agreements (Details) - USD ($) $ in Thousands |
3 Months Ended | 9 Months Ended | ||
---|---|---|---|---|
Sep. 30, 2020 |
Sep. 30, 2019 |
Sep. 30, 2020 |
Sep. 30, 2019 |
|
Total Research and Development - Licenses Acquired | $ 458 | $ 700 | $ 2,278 | $ 1,350 |
Research and clinical trial agreements [Member] | Aevitas | ||||
Total Research and Development - Licenses Acquired | 163 | 272 | 785 | 772 |
Research and clinical trial agreements [Member] | Aevitas | UMass - AAV [Member] | ||||
Total Research and Development - Licenses Acquired | 163 | 0 | 218 | 0 |
Research and clinical trial agreements [Member] | Aevitas | UPenn - AAV [Member] | ||||
Total Research and Development - Licenses Acquired | 0 | 255 | 567 | 755 |
Research and clinical trial agreements [Member] | Aevitas | Duke - AAV [Member] | ||||
Total Research and Development - Licenses Acquired | $ 0 | $ 17 | $ 0 | $ 17 |
X | ||||||||||
- Definition Research and development expense during the period related to the costs of developing and achieving technological feasibility of a computer software product to be sold, leased, or otherwise marketed. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
X | ||||||||||
- Details
|
X | ||||||||||
- Details
|
X | ||||||||||
- Details
|
X | ||||||||||
- Details
|
X | ||||||||||
- Details
|